Share on Facebook
Share on Twitter
Share on LinkedIn

The safety of Ariad Pharmaceuticals Inc. (ARIA)’s leukemia drug Iclusig is being investigated by U.S. regulators because of the increasing frequency of reports of serious blood clots and narrowing of blood vessels in patients.

“Health-care professionals should consider for each patient, whether the benefits of Iclusig treatment are likely to exceed the risks of treatment,” the U.S. Food and Drug Administration said today in a safety announcement. The agency urged doctors and patients to report side effects of the drug.

Click here to read more.